Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | SCD | O00767 | 1/20 | 0.40 |
| ▸ | AXL | P30530 | 1/20 | 0.40 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.40 |
| ▸ | MERTK | Q12866 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.37 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20162177 | 0.87 | KDM4C (0.46) | CYP3A4CYP2C9KDM4CKCNH2ASIC3 | |
| SCHEMBL20364372 | 0.87 | TAS2R8 (0.41) | HTR2CHTR2BSCDRIPK1MMP13 | |
| SCHEMBL20162130 | 0.86 | CYP3A4 (0.43) | CYP3A4CYP2C9KDM4CHTR2CHTR2B | |
| SCHEMBL20330427 | 0.86 | KDM4C (0.46) | CYP3A4CYP2C9KDM4CAXLTYRO3 | |
| SCHEMBL20162110 | 0.84 | KDM4C (0.45) | CYP3A4CYP2C9KDM4CHTR2CHTR2B | |
| SCHEMBL20367312 | 0.83 | KDM4C (0.43) | CYP3A4CYP2C9KDM4CKCNH2RIPK1 | |
| SCHEMBL20367479 | 0.83 | KDM4C (0.43) | CYP3A4CYP2C9KDM4CHTR2CHTR2B | |
| SCHEMBL20162172 | 0.83 | TAS2R8 (0.35) | RIPK1 | |
| SCHEMBL20330430 | 0.82 | KDM4C (0.42) | CYP3A4CYP2C9KDM4CSCDAXL | |
| SCHEMBL20367225 | 0.80 | KDM4C (0.48) | CYP3A4CYP2C9KDM4CKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10294237-B2 | Bicyclic heterocyclic amide derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2019-05-21 | — | — | US | claimed |
| US-20180194773-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2018-07-12 | — | — | US | claimed |
| EP-3323809-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2018-05-23 | — | — | EP | claimed |
| US-11434472-B2 | Agent for removing undifferentiated iPS cells | Sumitomo Pharma Co., Ltd. (JP) | 2022-09-06 | — | — | US | disclosed |
| US-20200268728-A1 | DRUG TARGETING CANCER STEM CELL | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2020-08-27 | — | — | US | disclosed |
| US-10294237-B2 | Bicyclic heterocyclic amide derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2019-05-21 | — | — | US | disclosed |
| US-10294237-B2 | Bicyclic heterocyclic amide derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2019-05-21 | — | — | US | disclosed |
| US-20180194773-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2018-07-12 | — | — | US | disclosed |
| US-20180194773-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2018-07-12 | — | — | US | disclosed |
| EP-3323809-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2018-05-23 | — | — | EP | disclosed |
| EP-3323809-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2018-05-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10294237-B2 | Bicyclic heterocyclic amide derivative | NR0B1, NR2E1, NR0B2 | CYP3A4 1261/4885CYP2C9 1569/4885KDM4C 1041/4885 |
| US-11434472-B2 | Agent for removing undifferentiated iPS cells | SALL4, NR4A2, NES | CYP3A4 2188/4885CYP2C9 4224/4885KDM4C 41/4885 |
| US-20200268728-A1 | DRUG TARGETING CANCER STEM CELL | NR5A1, NR3C1, NR3C2 | CYP3A4 350/4885CYP2C9 2034/4885KDM4C 578/4885 |
| US-20180194773-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | NR0B1, NR2E1, NR0B2 | CYP3A4 1261/4885CYP2C9 1569/4885KDM4C 1041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.